Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tscan Therapeutics, Inc.

1.92
-0.1000-4.95%
Pre-market: 1.85-0.0700-3.65%08:00 EST
Volume:309.21K
Turnover:600.13K
Market Cap:108.49M
PE:-0.92
High:2.04
Open:2.04
Low:1.87
Close:2.02
Loading ...

TScan Therapeutics Refinances Existing Convertible Debt Facility With Term Loan for up to $52.5 Million From Silicon Valley Bank

THOMSON REUTERS
·
23 Dec 2024

Press Release: TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

Dow Jones
·
23 Dec 2024

TScan Therapeutics Price Target Maintained With a $11.00/Share by Needham

Dow Jones
·
11 Dec 2024

TScan Therapeutics to present data from ongoing ALLOHA Phase 1 trial at ASH

TIPRANKS
·
10 Dec 2024

Morgan Stanley Keeps Their Buy Rating on TScan Therapeutics (TCRX)

TIPRANKS
·
05 Dec 2024

Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (TCRX), Legend Biotech (LEGN) and ICU Medical (ICUI)

TIPRANKS
·
13 Nov 2024

TScan Therapeutics Price Target Maintained With a $11.00/Share by Needham

Dow Jones
·
13 Nov 2024

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates

Zacks
·
12 Nov 2024

TScan Therapeutics Q3 2024 GAAP EPS $(0.25) Beats $(0.29) Estimate, Cash, Cash Equivalents, And Marketable Securities Of $271.1M Expected To Fund Operations Into The Fourth Quarter Of 2026

Benzinga
·
12 Nov 2024

TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock?

Zacks
·
07 Nov 2024

TScan Therapeutics Announces Upcoming Oral Presentation of Data From the Alloha™ Phase 1 Heme Trial at the 66TH American Society of Hematology Annual Meeting and Exposition

THOMSON REUTERS
·
05 Nov 2024

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39TH Annual Meeting

THOMSON REUTERS
·
04 Oct 2024

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

GlobeNewswire
·
04 Oct 2024